FMP

FMP

Enter

LMNL - Liminal BioSciences ...

Financial Summary of Liminal BioSciences Inc.(LMNL), Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of

photo-url-https://financialmodelingprep.com/image-stock/LMNL.png

Liminal BioSciences Inc.

LMNL

NASDAQ

Inactive Equity

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

8.5 USD

0.01 (0.118%)

About

ceo

Mr. Bruce Pritchard BA, CA, FIOD

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and ch...

CIK

0001351172

ISIN

CA53272L1031

CUSIP

53272L103

Address

440 Armand-Frappier Boulevard

Phone

14507810115

Country

CA

Employee

251

IPO Date

Dec 18, 2009

Summary

CIK

0001351172

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

53272L103

ISIN

CA53272L1031

Country

CA

Price

8.5

Beta

29.34

Volume Avg.

23.73k

Market Cap

27.62M

Shares

-

52-Week

3.1-8.5

DCF

2.85

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-1.24

P/B

-

Website

https://www.liminalbiosciences.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest LMNL News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep